However, even the lower estimates suggest that pertussis immunisation is highly desirable and efforts to improve coverage should be increased.
Public anxiety about the safety and efficacy of pertussis vaccine in the United Kingdom in the 1970s led to a sharp fall in vaccine uptake and a consequent increase in the severity of pertussis epidemics in 1977/9 and 1981/3.1 Fears about the safety of the whole cell vaccine have been addressed, but there is a continuing need to monitor vaccine efficacy, both for pertussis and other routinely administered vaccines. (table) . One non-notified probable case was admitted to hospital and B pertussis was identified from sputum culture.
Notified cases were more likely than probable cases to have a cough followed by whooping, although when children less than 8 years of age were considered slightly more of the non-notified probable cases reported whooping (63% compared with 59%). Notified cases had a slightly longer mean duration of cough than probable and possible cases (8-5 weeks compared with 6-2 weeks, p=0-01) and lost more days from school (7 4 days compared with 4-4 days, p<001 vaccine efficacy using notified cases was 13% greater than when both notified and nonnotified probable cases were used.
Another factor to be considered in interpreting these data is that estimates of pertussis vaccine efficacy will be expected to increase as the severity of disease used as a case definition increases. ' 2 There are two reasons for this: firstly, severe cases are more likely to be true pertussis and secondly, pertussis vaccine is known to reduce the severity of pertussis even when it fails to prevent disease. However, our data suggested that though notified cases had a more prolonged illness, severity as measured by frequency of coughing and complications rate was similar to that in the probable cases. The 13% difference in efficacy would appear to be the result of the notification bias.
Vaccine estimates which included possible cases (that is, without whooping, vomiting, or choking) were 5% lower than when only notified and probable cases were used. The possible cases occurred mainly in the second term and another infection may have been circulating. If so vaccine efficacy would be underestimated by including these possible cases in the calculations.
The vaccine efficacy estimate of 80% calculated by Jenkinson from cumulative data on 1-7 year olds from 1970-86 was based upon diagnostic criteria of paroxysmal cough for three or more weeks 'usually associated with vomiting and often whooping'.' This case definition is closer to our notified and probable cases for which we had an efficacy of 75%, with 95% confidence intervals including Jenkinson's estimate. Thus we have no evidence of a decline in efficacy for pertussis vaccine. Our data set was not large enough to examine efficacy within narrower age bands.
Routine monitoring of vaccine efficacy is highly desirable for several reasons.' 2 The prevailing antigenic composition of the disease organism may change causing a loss of vaccine efficacy. Different commercial vaccines and even batches of the same vaccine will not have identical efficacies and monitoring may help to identify problems in production. Incorrect storage and administration as well as changes to the recommended dose, timing, frequency, and age at vaccination may be associated with reduced efficacy. Furthermore, as vaccine cover improves the proportion of cases vaccinated will increase without any fall in the efficacy. This concept is not readily appreciated and continued demonstration of efficacy will be important in maintaining confidence in the vaccine. Locally generated estimates may be more persuasive than national data in local health promotion efforts. Various methods for estimating efficacy based upon locally generated data have been proposed for local use.8 However, our data suggest that notifications may give significantly biased estimates. Where possible cohort and case-control studies should use unbiased samples of cases identified by active case searching.
The attempts to improve uptake of the third protective dose of pertussis vaccine in children under 8 years old in Pembrokeshire were reasonably successful. About half of the children who could have benefited from a single extra dose received it within a month. No improvement in uptake among never vaccinated children was observed. The new two, three, four month schedule for pertussis vaccine introduced in 1989 in the United Kingdom now makes the accelerated schedule for outbreaks redundant.
Did Alice have glandular fever? Here's one to test your diagnostic acumen. Did you know about the relationship between metamorphopsia and infectious mononucleosis? As you know, metamorphopsia is a form of illusion in which the form, size, movement, or colour of objects is distorted. It has been related to lesions in the occipital lobes or in the occipitotemporal or occipitoparietal regions.
In children it may be caused by infectious mononucleosis. Three children so affected were described in 1977' and Lahat and colleagues have recently described a 6 year old girl from Israel (7ournal ofNeurology, Neurosurgery, and Psychiatry 1990;53:1104).
The child described the visual illusions in association with mild headache coming on two weeks after the onset of glandular fever. The episodes lasted a few minutes each time and occurred several times a day. Cranial computed tomography was normal but an EEG showed sharp high voltage waves in the parieto-occipital region. Two weeks later the EEG was normal. The symptoms lasted for four weeks.
Metamorphopsia has been called the Alice in Wonderland syndrome.2 Apparently it can come on before, with, or after the other features of glandular fever. 
